JP2023505192A - 養子細胞療法としての遺伝子操作された二重陰性ｔ細胞 - Google Patents

養子細胞療法としての遺伝子操作された二重陰性ｔ細胞 Download PDF

Info

Publication number
JP2023505192A
JP2023505192A JP2022533347A JP2022533347A JP2023505192A JP 2023505192 A JP2023505192 A JP 2023505192A JP 2022533347 A JP2022533347 A JP 2022533347A JP 2022533347 A JP2022533347 A JP 2022533347A JP 2023505192 A JP2023505192 A JP 2023505192A
Authority
JP
Japan
Prior art keywords
cells
dnt
genetically modified
population
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505192A5 (https=
Inventor
リー チャン
ジョン ボク イ
ダニエル ヴァシッチ
イスマット カトリ
ダラム ライ
ユキ シー ロン レウン
Original Assignee
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2023505192A publication Critical patent/JP2023505192A/ja
Publication of JP2023505192A5 publication Critical patent/JP2023505192A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022533347A 2019-12-06 2020-12-07 養子細胞療法としての遺伝子操作された二重陰性ｔ細胞 Pending JP2023505192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944634P 2019-12-06 2019-12-06
US62/944,634 2019-12-06
PCT/CA2020/051682 WO2021108926A1 (en) 2019-12-06 2020-12-07 Genetically engineered double negative t cells as an adoptive cellular therapy

Publications (2)

Publication Number Publication Date
JP2023505192A true JP2023505192A (ja) 2023-02-08
JP2023505192A5 JP2023505192A5 (https=) 2023-12-11

Family

ID=76221295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533347A Pending JP2023505192A (ja) 2019-12-06 2020-12-07 養子細胞療法としての遺伝子操作された二重陰性ｔ細胞

Country Status (6)

Country Link
US (1) US20230011889A1 (https=)
EP (1) EP4069831A4 (https=)
JP (1) JP2023505192A (https=)
CN (1) CN114929865A (https=)
CA (1) CA3160422A1 (https=)
WO (1) WO2021108926A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113528449A (zh) * 2020-04-20 2021-10-22 浙江瑞加美生物科技有限公司 一种制备通用型人源化car19-dnt细胞的技术及其应用
EP4458378A4 (en) * 2021-12-30 2025-07-09 Chongqing Prec Biotech Co Ltd TECHNIQUE FOR PREPARING A UNIVERSAL CAR-T CELL, AND APPLICATION OF A UNIVERSAL CAR-T CELL
WO2025106552A1 (en) * 2023-11-14 2025-05-22 Nkarta, Inc. Methods and compositions for treatment of leukemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110052554A1 (en) * 2008-01-30 2011-03-03 Memorial Sloan-Kettering Cancer Center Methods for off-the- shelf tumor immunotherapy using allogeneic t-cell precursors
CN104789595A (zh) * 2015-04-20 2015-07-22 范国煌 嵌合抗原受体双阴性t细胞的构建方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350243B2 (en) * 2008-01-30 2019-07-16 Memorial Sloan-Kettering Cancer Center Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors
CN107828730B (zh) * 2017-11-07 2019-04-30 南京北恒生物科技有限公司 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110052554A1 (en) * 2008-01-30 2011-03-03 Memorial Sloan-Kettering Cancer Center Methods for off-the- shelf tumor immunotherapy using allogeneic t-cell precursors
CN104789595A (zh) * 2015-04-20 2015-07-22 范国煌 嵌合抗原受体双阴性t细胞的构建方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J IMMUNOTHER CANCER, vol. vol. 7(1), JPN6024050992, 22 January 2019 (2019-01-22), pages 17 - 1, ISSN: 0005485760 *

Also Published As

Publication number Publication date
CN114929865A (zh) 2022-08-19
CA3160422A1 (en) 2021-06-10
WO2021108926A1 (en) 2021-06-10
US20230011889A1 (en) 2023-01-12
EP4069831A1 (en) 2022-10-12
EP4069831A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
Marofi et al. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
US11717539B2 (en) Combination immune therapy and cytokine control therapy for cancer treatment
Lee et al. Allogeneic human double negative T cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms
JP7032304B2 (ja) キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用
ES2627910T3 (es) Métodos para potenciar la proliferación y la actividad de células destructoras naturales
US12274714B2 (en) Early apoptotic cells for use treating sepsis
Kroesen et al. A transplantable TH‐MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma
US20220275334A1 (en) Nk cell compositions and preparations for immunotherapy and methods for their production
US11534460B2 (en) Method for expansion of double negative regulatory T cells
Lichtenegger et al. Current strategies in immunotherapy for acute myeloid leukemia
KR102661091B1 (ko) Nk 세포의 골수 호밍을 개선시키는 pm21 입자
JP6096677B2 (ja) 同種造血幹細胞移植の増強
Fang et al. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
JP2023505192A (ja) 養子細胞療法としての遺伝子操作された二重陰性ｔ細胞
JP2022515144A (ja) オフザシェルフのダブルネガティブｔ細胞の産生および治療的使用
Xia et al. Tracking ex vivo-expanded CD4+ CD25+ and CD8+ CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease
CN107073039A (zh) 用于癌症治疗的免疫疗法
US10201572B2 (en) Combination therapy with double negative T-cells
EP4031655A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
CN114729314A (zh) 用于癌症治疗的组合癌症疗法和细胞因子控制疗法
Wang et al. A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies
Katsumata et al. Evaluation of the impact of conventional immunosuppressant on the establishment of murine transplantation tolerance–an experimental study
Minina et al. CAR cells beyond classical CAR T cells: functional properties and prospects of application
HK40079239A (en) Genetically engineered double negative t cells as an adoptive cellular therapy
Sen Targeting Siglecs on Recipient Antigenpresenting Cells With Sialic Acid-Modified Alloantigen to Promote Transplantation Tolerance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260402